Ipsen (FR:IPN) has released an update.
Ipsen’s Iqirvo (elafibranor) shows promising long-term efficacy and safety in treating primary biliary cholangitis (PBC), with significant improvements in symptoms such as fatigue and pruritus over three years. The data, presented at the AASLD congress, bolsters Iqirvo’s potential as a leading treatment choice for PBC, having been approved in several major markets in 2024.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
